Zoledronic acid 5 mg (Aclasta®) - reviewed by Penny Hunt and Sunita Paul

In this review:

Osteoporosis
Paget’s disease
Advantages of zoledronic acid over available treatment options
Pharmacological properties of zoledronic acid
Current registered uses of zoledronic acid in New Zealand
Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease
Long-term control of bone turnover in Paget’s disese with zoledronic acid and risedronate

Please login below to download this issue (PDF)

Subscribe